Ftse Mib
34.145,86
-0,28%
DAX
18.498,38
0,32%
S&P 500
5.183,80
-0,08%
NASDAQ
16.294,24
-0,23%
Bitcoin
62.421,62
0,14%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BeiGene Ltd (BGNE) BeiGene Ltd (BGNE) Notizie

BeiGene Ltd

BGNE
162,135
1,58 (0,98%)
Ultimo aggiornamento: 17:36:31
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/5/202412:00BWBeiGene Reports First Quarter 2024 Financial Results and..
26/4/202416:34BWBeiGene Demonstrates Global Progress in 2023 Responsible..
25/4/202413:11BWGlobaler Onkologie-Innovator BeiGene präsentiert auf der..
25/4/202413:10BWBeiGene, innovateur mondial en oncologie, présente de..
24/4/202422:01BWGlobal Oncology Innovator BeiGene Highlights New Data across..
24/4/202401:31BWBeiGene erhält von der EU-Kommission die Zulassung für..
23/4/202412:00BWBeiGene Receives European Commission Approval for..
16/3/202416:18BWBeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得
15/3/202422:13BW百濟神州喜獲FDA批准，TEVIMBRA®將用於晚期或轉移性食管鱗狀細胞癌在化療後的治療
15/3/202421:02BWBeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans..
15/3/202407:06BWBeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung..
14/3/202421:28BWBeiGene Receives FDA Approval for TEVIMBRA® for the..
14/3/202415:23BWマックス財団、ベイジーン、ベイジーン財団の協力により、低・中所得国の慢性リンパ性白血病患者にBRUKINSA®を初回投与
14/3/202410:31BWThe Max Foundation、BeiGene和BeiGene..
13/3/202420:01BWLes premières doses de BRUKINSA® sont administrées à des..
13/3/202413:00BWFirst Doses of BRUKINSA® provided to Patients with Chronic..
07/3/202423:19BWBeiGene Announces FDA Accelerated Approval of BRUKINSA for..
06/3/202412:00BWBeiGene to Present Clinical and Preclinical Data from Broad..
29/2/202417:17BWベイジーン、2023年第4・四半期および通期決算と事業に関する最新情報を発表
29/2/202416:00BWBeiGene Announces New Efficacy Analysis Comparing BRUKINSA®..
29/2/202401:56BWBeiGene publie ses résultats financiers du quatrième..
28/2/202419:13BWBeiGene meldet Finanzergebnisse für das vierte Quartal und..
28/2/202414:05BWBeiGene to Present at Upcoming Investor Conferences
28/2/202413:43BWベイジーン、非小細胞肺がん治療薬チスレリズマブに対してCHMPから肯定的意見を受領
28/2/202412:48BWBeiGene公布2023年第四季及全年財務業績和最新業務情況
27/2/202413:24BW百濟神州（BeiGene）獲得 CHMP 對替雷利珠單抗（Tislelizumab）治療非小細胞肺癌的積極意見
27/2/202413:22BWBeiGene erhält positives CHMP-Gutachten für Tislelizumab zur..
27/2/202412:00BWBeiGene’s Biologics License Application for TEVIMBRA®..
26/2/202412:02EDGAR2Form 8-K - Current report
26/2/202412:00BWBeiGene Reports Fourth Quarter and Full Year 2023 Financial..
26/2/202411:00BWBeiGene Receives Positive CHMP Opinion for Tislelizumab as..
07/2/202412:47PRNCAHealth Canada Approves BRUKINSA® (zanubrutinib) for the..
31/1/202412:47PRNCALes adultes atteints de leucémie lymphoïde chronique (LLC)..
24/1/202420:03BWベイジーン、取締役会に経験豊富なライフサイエンス界のエグゼクティブ、オリビエ・ブランディクールを迎える
23/1/202418:04BWBeiGene accueille au sein de son conseil d'administration,..
23/1/202417:55BWBeiGene heißt den erfahrenen Life Sciences Manager Olivier..
23/1/202412:03EDGAR2Form 8-K - Current report
23/1/202412:00BWBeiGene Welcomes Experienced Life Sciences Executive Olivier..
22/12/202312:00BWFDA Approves Label Update for BRUKINSA® (zanubrutinib) in..
21/12/202312:01BWBeiGene to Present at the 42nd Annual J.P. Morgan Healthcare..
29/11/202322:01BWBeiGene to Host ASH Investor Meeting in Person and via..
28/11/202312:00BWBeiGene to Present New Data Highlighting Hematology..
21/11/202312:00BWBeiGene and Ensem Therapeutics Announce Partnership to..
17/11/202312:00BWBeiGene Receives European Commission Approval for BRUKINSA®..
09/11/202322:08EDGAR2Form 8-K - Current report
09/11/202322:01BWBeiGene Continues Global Growth with Third Quarter 2023..
08/11/202312:00BWBeiGene to Present at the Jefferies London Healthcare..
20/10/202322:04EDGAR2Form 8-K - Current report
20/10/202312:00BWBRUKINSA® Receives Positive Recommendation from NICE in U.K...
17/10/202322:01BWBeiGene Announces Late-Breaking Data at ESMO Showing..
Apertura: 165,49 Min: 161,78 Max: 168,46
Chiusura: 160,56

La tua Cronologia

NASDAQ
BGNE
BeiGene
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network